Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70:86–104.

Article  PubMed  Google Scholar 

Fischer JW, Bhattarai N. CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. Front Immunol. 2021;12:693016.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruppel KE, Fricke S, Köhl U, Schmiedel D. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy. Front Immunol. 2022;13:822298.

Article  CAS  PubMed  PubMed Central  Google Scholar 

June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5.

Article  CAS  PubMed  Google Scholar 

O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9:eaaa0984. https://doi.org/10.1126/scitranslmed.aaa0984.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med. 1978;148:1687–98.

Article  CAS  PubMed  Google Scholar 

Sanber K, Savani B, Jain T. Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br J Haematol. 2021;195:660–8.

Article  CAS  PubMed  Google Scholar 

Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100:1265–73.

Article  CAS  PubMed  Google Scholar 

Marofi F, Saleh MM, Rahman HS, Suksatan W, Al-Gazally ME, Abdelbasset WK, et al. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Res Ther. 2021;12:1–18.

Article  Google Scholar 

Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2017;32:520–31.

Article  PubMed  PubMed Central  Google Scholar 

Vivier E, Nunès JA, Vély F. Natural killer cell signaling pathways. Science. 2004;306:1517–9.

Article  CAS  PubMed  Google Scholar 

Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci USA. 1993;90:12000–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T, et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2008;40:84–90.

Article  CAS  PubMed  Google Scholar 

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–100.

Article  CAS  PubMed  Google Scholar 

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382:545–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirayama D, Iida T, Nakase H. The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis. Int J Mol Sci. 2017;19:92. https://doi.org/10.3390/ijms19010092.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suzuki T, Arumugam P, Sakagami T, Lachmann N, Chalk C, Sallese A, et al. Pulmonary macrophage transplantation therapy. Nature. 2014;514:450–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rafiei Hashtchin A, Fehlhaber B, Hetzel M, Manstein F, Stalp JL, Glage S, et al. Human iPSC-derived macrophages for efficient Staphylococcus aureus clearance in a murine pulmonary infection model. Blood Adv. 2021;5:5190–201.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cannac M, Nikolic J, Benaroch P. Cancer Immunotherapies Based on Genetically Engineered Macrophages. Cancer Immunol Res. 2022;10:1156–66.

Article  CAS  PubMed  Google Scholar 

Brempelis KJ, Cowan CM, Kreuser SA, Labadie KP, Prieskorn BM, Lieberman NAP, et al. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses. J Immunother Cancer. 2020;8:e001356. https://doi.org/10.1136/jitc-2020-001356.

Article  PubMed  PubMed Central  Google Scholar 

Hourani T, Holden JA, Li W, Lenzo JC, Hadjigol S, O’Brien-Simpson NM. Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting. Front Oncol. 2021;11:788365.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morrissey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, et al. Chimeric antigen receptors that trigger phagocytosis. Elife. 2018;7:e36688. https://doi.org/10.7554/eLife.36688.

Article  PubMed  PubMed Central  Google Scholar 

Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121:837–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27:1–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rogers GL, Cannon PM. Genome edited B cells: a new frontier in immune cell therapies. Mol Ther. 2021;29:3192–204.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nahmad AD, Raviv Y, Horovitz-Fried M, Sofer I, Akriv T, Nataf D, et al. Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. Nat Commun. 2020;11:5851.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fink JR, LeBien TW. Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors. Exp Hematol. 2001;29:490–8.

Article  CAS  PubMed  Google Scholar 

Largeot A, Pagano G, Gonder S, Moussay E, Paggetti J. The B-side of Cancer Immunity: The Underrated Tune. Cells. 2019;8:449. https://doi.org/10.3390/cells8050449.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuen GJ, Demissie E, Pillai S. B lymphocytes and cancer: a love-hate relationship. Trends Cancer Res. 2016;2:747–57.

Article  Google Scholar 

Schmidt P, Raftery MJ, Pecher G. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology. Front Immunol. 2020;11:611163.

Article  CAS  PubMed  Google Scholar 

Sabbah M, Jondreville L, Lacan C, Norol F, Vieillard V, Roos-Weil D, et al. CAR-NK Cells: A Chimeric Hope or a Promising Therapy? Cancers. 2022;14:3839. https://doi.org/10.3390/cancers14153839.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bai Y, Soda Y, Izawa K, Tanabe T, Kang X, Tojo A, et al. Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector. Gene Ther. 2003;10:1446–57.

Article  CAS  PubMed  Google Scholar 

Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32:1529–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA. 2006;103:17372–7.